LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer

doi:10.3748/wjg.v25.i29.3972

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 29

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8844)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

537

WORD

297

HTML

4195

Figures (1-5)

519

Tables (1-3)

514

Sum=6062

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

895

Download

1889

Sum=2784

Aug 7, 2019 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (50)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Basic Study

World J Gastroenterol. Aug 7, 2019; 25(29): 3972-3984
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.3972

LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer

Wei Wang, Ying Xie, Fei Chen, Xu Liu, Li-Li Zhong, Hai-Qiang Wang, Qing-Chang Li

Wei Wang, Qing-Chang Li, College of Basic Medical Sciences, China medical University and Department of Pathology, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

Wei Wang, Teaching and Research Department of Pathology, Basic Medical College, Heilongjiang University of Traditional Chinese Medicine, Harbin 150040, Heilongjiang Province, China

Ying Xie, Fei Chen, Department of Synopsis of The Golden Chamber, School of Basic Medical Sciences, Heilongjiang University of Traditional Chinese Medicine, Harbin 150040, Heilongjiang Province, China

Xu Liu, Experiment and Training Center, Heilongjiang University of Traditional Chinese Medicine, Harbin 150040, Heilongjiang Province, China

Li-Li Zhong, Department of Pathology, the First Clinical Medical College, Heilongjiang University of Traditional Chinese Medicine, Harbin 150040, Heilongjiang Province, China

Hai-Qiang Wang, Department of Gastroenterology, the First Clinical Medical College, Heilongjiang University of Traditional Chinese Medicine, Harbin 150040, Heilongjiang Province, China

Author contributions: Li QC designed the research; Wang W, Xie Y, Chen F, Liu X, Zhong LL and Wang HQ performed the research; Wang W and Xie Y analyzed the data; Wang W and Li QC wrote the paper.

Institutional review board statement: This study was reviewed and approved by the Institutional Review Board Committee of the First Affiliated Hospital of China Medical University.

Conflict-of-interest statement: We declare no conflicts of interest.

Corresponding author: Qing-Chang Li, PhD, Doctor, College of Basic Medical Sciences, China medical University and Department of Pathology, the First Affiliated Hospital of China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang 110001, Liaoning Province, China. sci18846185819@126.com

Telephone: +86-24-62255001

Received: April 28, 2019
Peer-review started: April 28, 2019
First decision: May 24, 2019
Revised: June 7, 2019
Accepted: June 25, 2019
Article in press: June 26, 2019
Published online: August 7, 2019
Processing time: 102 Days and 23.1 Hours

Abstract

BACKGROUND

Colorectal cancer (CRC) is the third most prevalent malignancy and has the fourth highest global cancer mortality rate. Early diagnosis and prompt medical attention can improve quality of life and the prognosis of CRC patients. Accumulating evidence reveals that long non-coding RNAs (lncRNAs) function as oncogenes or anti-oncogenes, as well as biomarkers in various cancers.

AIM

To investigate the levels and molecular mechanism of the lncRNA maternally expressed gene 3 (MEG3) in CRC.

METHODS

The levels of lncRNA MEG3 in CRC tissue, serum and cell line samples were explored via qRT-PCR. The relationship between MEG3 levels and clinicopathological features in CRC was investigated. The diagnostic and prognostic values of serum MEG3 levels were analyzed with ROC curves and Kaplan‑Meier survival curves, respectively.

RESULTS

Significant decreased levels of MEG3 existed in CRC tissue, cell lines and serum. CRC patients with down-regulated serum MEG3 levels had larger tumor sizes, and advanced clinical stages. The sensitivity and specificity of serum MEG3 levels in CRC detection was 0.667 and 0.875, respectively. Tumor size, T stages, and serum MEG3 levels are indie factors that produce an effect on CRC patients' prognosis. Kaplan‑Meier survival curves suggested that CRC patients with high levels of MEG3 had a remarkably better overall survival rate.

CONCLUSION

LncRNA MEG3 is down-regulated in CRC, and regulates cell functions by targeting adenosine deaminase’s effect on RNA 1 in CRC.

Keywords: LncRNA; Maternally expressed gene 3; Biomarker; Colorectal cancer; Adenosine deaminase acting on RNA 1

Core tip: Long non-coding RNA (LncRNA) maternally expressed gene 3 (MEG3) is down-regulated in tissue, cell lines and serum. Colorectal cancer (CRC) patients with down-regulated serum MEG3 levels were had larger tumor sizes, and advanced clinical stages. LncRNA MEG3 functions as a diagnostic and prognostic marker in CRC. LncRNA MEG3 promotes cell proliferation and induced apoptosis in CRC. The effect of adenosine deaminase on RNA 1 may be the target of lncRNA MEG3 in CRC.